Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Nextrna Therapeutics Inc.
Headquarters: Cambridge, MA, United States of America
Website: https://www.nextrnatx.com/
Year Founded: 2020
Status: Private
See Emerging Company Profile .
BioCentury | Sep 26, 2024
Management Tracks
Century names CFO, CSO
Plus: Freenome’s CEO Nolan resigns and updates from NextRNA and Abiologics
BioCentury | Sep 4, 2024
Deals
Deals Report: Pfizer collaborates with second Flagship company, three China deals, and more
BioCentury’s weekly deals analysis
BioCentury | Nov 30, 2022
Data Byte
Rgenta’s A round adds fuel to RNA-targeting small molecule space
$52M round led by AstraZeneca’s joint fund with China International Capital
BioCentury | Sep 1, 2022
Management Tracks
Accelerating talent out of academia
Nucleate and SPARK provide case studies in readying grad students and postdocs for industry
BioCentury | Aug 12, 2022
Management Tracks
Davis named CEO at PsiOxus
Plus CEO Gill to transition to chair, and updates from NextRNA, Eli Lilly and more
BioCentury | Mar 3, 2022
Emerging Company Profile
NextRNA: small molecules take on lncRNA-protein interactions
With $56M, the Dana-Farber spinout is developing RNA- and protein-targeting therapies for cancer and immunology
Items per page:
1 - 6 of 6